2024
Hypofractionated vs Conventionally Fractionated Postmastectomy Radiation After Implant-Based Reconstruction
Wong J, Uno H, Tramontano A, Fisher L, Pellegrini C, Abel G, Burstein H, Chun Y, King T, Schrag D, Winer E, Bellon J, Cheney M, Hardenbergh P, Ho A, Horst K, Kim J, Leonard K, Moran M, Park C, Recht A, Soto D, Shiloh R, Stinson S, Snyder K, Taghian A, Warren L, Wright J, Punglia R. Hypofractionated vs Conventionally Fractionated Postmastectomy Radiation After Implant-Based Reconstruction. JAMA Oncology 2024, 10 PMID: 39115975, PMCID: PMC11310844, DOI: 10.1001/jamaoncol.2024.2652.Peer-Reviewed Original ResearchFunctional Assessment of Cancer Therapy-BreastPhysical well-beingPostmastectomy radiation therapyImplant-based reconstructionConventional fractionationStudy armsPhysical well-being scoresUS cancer centersLocal-regional disease controlImprove quality of lifeQuality of lifeAs-treated cohortChest wall doseHigher adverse eventsToxic effectsMain OutcomesRandomized clinical trialsPWB scoreUnpaid timePostmastectomy radiationImplant reconstructionRadiation therapyTreatment breaksImplant-basedImprovement changesHelping ourselves, helping others: the Young Women’s Breast Cancer Study (YWS) – a multisite prospective cohort study to advance the understanding of breast cancer diagnosed in women aged 40 years and younger
Rosenberg S, Zheng Y, Ruddy K, Poorvu P, Snow C, Kirkner G, Meyer M, Tamimi R, Schapira L, Peppercorn J, Come S, Borges V, Warner E, Gelber S, Collins L, Winer E, Partridge A. Helping ourselves, helping others: the Young Women’s Breast Cancer Study (YWS) – a multisite prospective cohort study to advance the understanding of breast cancer diagnosed in women aged 40 years and younger. BMJ Open 2024, 14: e081157. PMID: 38951008, PMCID: PMC11218027, DOI: 10.1136/bmjopen-2023-081157.Peer-Reviewed Original ResearchConceptsYoung Women's Breast Cancer StudyMultisite prospective cohort studyBreast Cancer StudyProspective cohort studyStage 0-IV breast cancerBreast cancerCohort studyOlder womenDied of breast cancerFear of recurrencePatient-reported outcome dataYoung womenCancer studiesClinical data abstractionPost-traumatic stressQuality of lifeImprove careFollow-upPsychosocial outcomesYoung survivorsCommunity sitesBiospecimen collectionUnderstudied populationData abstractionOutcome data
2022
Aiming at a Tailored Cure for ERBB2-Positive Metastatic Breast Cancer
Tarantino P, Curigliano G, Parsons HA, Lin NU, Krop I, Mittendorf EA, Waks A, Winer EP, Tolaney SM. Aiming at a Tailored Cure for ERBB2-Positive Metastatic Breast Cancer. JAMA Oncology 2022, 8: 629-635. PMID: 35024766, DOI: 10.1001/jamaoncol.2021.6597.Peer-Reviewed Original ResearchConceptsErbB2-positive metastatic breast cancerMetastatic breast cancerPopulation of patientsBreast cancerDe novo metastaticErb-b2 receptor tyrosine kinase 2High ERBB2 expressionCurrent treatment algorithmsHigh-dose chemotherapyLong-term respondersFraction of patientsAntitumor immune activationReceptor tyrosine kinase 2Quality of lifeOverall survivalSystemic treatmentTrastuzumab deruxtecanPathologic featuresTreatment algorithmFrontline treatmentImmune activationBiologic treatmentPathologic termsDisease burdenLong-term benefits
2021
Exploring the impact of exercise and mind–body prehabilitation interventions on physical and psychological outcomes in women undergoing breast cancer surgery
Knoerl R, Giobbie-Hurder A, Sannes TS, Chagpar AB, Dillon D, Dominici LS, Frank ES, Golshan M, McTiernan A, Rhei E, Tolaney SM, Winer EP, Yung RL, Irwin ML, Ligibel JA. Exploring the impact of exercise and mind–body prehabilitation interventions on physical and psychological outcomes in women undergoing breast cancer surgery. Supportive Care In Cancer 2021, 30: 2027-2036. PMID: 34648061, DOI: 10.1007/s00520-021-06617-8.Peer-Reviewed Original ResearchConceptsCancer treatment-related symptomsPrehabilitation interventionsTreatment-related symptomsTime of enrollmentImpact of exerciseQuality of lifeBreast cancerGroup participantsPre-operative exerciseBreast cancer surgeryMind-body interventionsCognitive functioningOpportunity trialCancer surgeryOutcome measuresSecondary analysisOne monthSurgeryMeasures of qualityGroup comparisonsCancer diagnosisCancerWomenInterventionSignificant differencesALEXANDRA/IMpassion030: A phase 3 study of standard adjuvant chemotherapy with or without atezolizumab in patients with early-stage triple-negative breast cancer.
Saji S, McArthur H, Ignatiadis M, Bailey A, El-Abed S, Brandao M, Metzger O, Lai C, Guillaume S, Fumagalli D, Agbor-tarh D, Seiller A, Xifro R, Honvault V, Viale G, DuFrane C, Barata T, Winer E, Gelber R, Piccart-Gebhart M. ALEXANDRA/IMpassion030: A phase 3 study of standard adjuvant chemotherapy with or without atezolizumab in patients with early-stage triple-negative breast cancer. Journal Of Clinical Oncology 2021, 39: tps597-tps597. DOI: 10.1200/jco.2021.39.15_suppl.tps597.Peer-Reviewed Original ResearchTriple-negative breast cancerInvasive disease-free survivalEarly-stage triple-negative breast cancerPD-L1Breast cancerAdjuvant chemotherapyStage triple-negative breast cancerMetastatic triple-negative breast cancerPD-L1 negative tumorsF. Hoffmann-La Roche LtdBreast International GroupOperable stage IIRandomized phase 3Same chemotherapy regimenStandard adjuvant chemotherapyCentral pathology reviewDisease-free survivalPD-L1 statusPhase 3 studyPhase 3 trialType of surgeryNegative breast cancerQuality of lifeAtezolizumab 1200Weekly paclitaxel
2017
Lymphedema, musculoskeletal events and arm function in older patients receiving adjuvant chemotherapy for breast cancer (Alliance A171302)
Hopkins JO, Allred J, Hurria A, Jatoi A, Lafky JM, Cohen H, Hudis C, Winer E, Mandelblatt J, Partridge A, Carey L, Muss HB. Lymphedema, musculoskeletal events and arm function in older patients receiving adjuvant chemotherapy for breast cancer (Alliance A171302). Breast Cancer Research And Treatment 2017, 166: 793-808. PMID: 28825227, PMCID: PMC5771504, DOI: 10.1007/s10549-017-4454-7.Peer-Reviewed Original ResearchConceptsQuality of lifeArm functionBreast cancerAdjuvant chemotherapyMusculoskeletal eventsPhysician-reported adverse eventsIncidence of lymphedemaAxillary node dissectionType of chemotherapyEORTC QLQ-BR23Breast cancer treatmentImpact of treatmentDetection of lymphedemaCALGB 49907Node dissectionAdverse eventsOlder patientsQLQ-BR23Standard therapyStudy entryWomen 65Month 2Elderly womenPatientsChemotherapySurvival benefit needed to undergo chemotherapy: Patient and physician preferences
Vaz‐Luis I, O'Neill A, Sepucha K, Miller KD, Baker E, Dang CT, Northfelt DW, Winer EP, Sledge GW, Schneider B, Partridge AH. Survival benefit needed to undergo chemotherapy: Patient and physician preferences. Cancer 2017, 123: 2821-2828. PMID: 28323331, PMCID: PMC5517352, DOI: 10.1002/cncr.30671.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAntineoplastic Combined Chemotherapy ProtocolsAttitude of Health PersonnelAttitude to HealthBevacizumabBreast NeoplasmsChemotherapy, AdjuvantClinical Trials, Phase III as TopicCyclophosphamideDoxorubicinFemaleHumansMastectomyMastectomy, SegmentalMiddle AgedPaclitaxelPatient PreferencePhysiciansQuality of LifeRandomized Controlled Trials as TopicRisk AssessmentSurveys and QuestionnairesSurvival RateTumor BurdenConceptsMonths of chemotherapyModest survival benefitSurvival benefitAdjuvant chemotherapyEarly-stage breast cancerContemporary adjuvant chemotherapyPhase 3 trialBreast cancer patientsStage breast cancerQuality of lifeMonths of benefitsAdjuvant cyclophosphamideAdjuvant doxorubicinChemotherapy regimenMost patientsUndergoing ChemotherapyCancer patientsPatient preferencesBreast cancerModest benefitOld regimenChemotherapyPatientsPhysician's choiceSerial surveys
2016
Extending Aromatase-Inhibitor Adjuvant Therapy to 10 Years
Goss PE, Ingle JN, Pritchard KI, Robert NJ, Muss H, Gralow J, Gelmon K, Whelan T, Strasser-Weippl K, Rubin S, Sturtz K, Wolff AC, Winer E, Hudis C, Stopeck A, Beck JT, Kaur JS, Whelan K, Tu D, Parulekar WR. Extending Aromatase-Inhibitor Adjuvant Therapy to 10 Years. New England Journal Of Medicine 2016, 375: 209-219. PMID: 27264120, PMCID: PMC5024713, DOI: 10.1056/nejmoa1604700.Peer-Reviewed Original ResearchConceptsContralateral breast cancerDisease-free survivalAromatase inhibitorsBreast cancerOverall survivalDisease-free survival ratesPositive early breast cancerAdjuvant aromatase inhibitorsNew-onset osteoporosisPlacebo-controlled trialPrimary end pointEarly breast cancerAnnual incidence rateTreatment of choiceBreast cancer recurrenceExtension of treatmentQuality of lifeBone painLetrozole groupAdjuvant therapyPlacebo groupPostmenopausal womenDisease recurrenceIncidence rateLower incidenceAdjuvant Endocrine Therapy for Women With Hormone Receptor–Positive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update on Ovarian Suppression
Burstein HJ, Lacchetti C, Anderson H, Buchholz TA, Davidson NE, Gelmon KE, Giordano SH, Hudis CA, Solky AJ, Stearns V, Winer EP, Griggs JJ. Adjuvant Endocrine Therapy for Women With Hormone Receptor–Positive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update on Ovarian Suppression. Journal Of Clinical Oncology 2016, 34: 1689-1701. PMID: 26884586, DOI: 10.1200/jco.2015.65.9573.Peer-Reviewed Original ResearchConceptsReceptor-positive breast cancerAdjuvant endocrine therapyOvarian suppressionStandard adjuvant therapyEndocrine therapyBreast cancerAdjuvant chemotherapyAdjuvant therapyAromatase inhibitorsClinical Oncology Clinical Practice Guideline UpdateHormone receptor-positive breast cancerEstrogen receptor-positive breast cancerClinical Practice Guideline UpdateStage I breast cancerDisease-free survivalHigh-risk patientsLow-risk patientsI breast cancerSubset of patientsOverall clinical benefitRandomized clinical trialsNode-negative cancersQuality of lifeDistant recurrencePremenopausal womenRandomized trial of a physical activity intervention in women with metastatic breast cancer
Ligibel JA, Giobbie-Hurder A, Shockro L, Campbell N, Partridge AH, Tolaney SM, Lin NU, Winer EP. Randomized trial of a physical activity intervention in women with metastatic breast cancer. Cancer 2016, 122: 1169-1177. PMID: 26872302, DOI: 10.1002/cncr.29899.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedBreast NeoplasmsChemotherapy, AdjuvantChi-Square DistributionCombined Modality TherapyDisease-Free SurvivalExercise TherapyFemaleFollow-Up StudiesHumansMastectomy, SegmentalMiddle AgedNeoplasm InvasivenessNeoplasm StagingPhysical FitnessQuality of LifeRadiotherapy, AdjuvantReference ValuesSurvival AnalysisTreatment OutcomeUnited StatesConceptsMetastatic breast cancerEarly-stage breast cancerExercise interventionBreast cancerPhysical functioningLife Questionnaire-Core 30 questionnaireModerate-intensity aerobic exercisePhysical Activity Recall interviewModerate-intensity exercise interventionAdvanced breast cancerPhysical activity interventionsTime of enrollmentWait-list control groupQuality of lifeMetastatic diseaseCancer QualityMedian ageIntervention armMedian timeActivity interventionsAerobic exerciseWeekly exerciseTreadmill testFunctional capacityNonsignificant increase
2015
Ovarian function suppression, symptom burden, and quality of life in young women with breast cancer: A prospective study.
Rosenberg S, Ruddy K, Tamimi R, Gelber S, Schapira L, Borges V, Come S, Meyer M, Winer E, Partridge A. Ovarian function suppression, symptom burden, and quality of life in young women with breast cancer: A prospective study. Journal Of Clinical Oncology 2015, 33: 515-515. DOI: 10.1200/jco.2015.33.15_suppl.515.Peer-Reviewed Original Research
2013
A planned, prospective comparison of short-term quality of life outcomes among older patients with breast cancer treated with standard chemotherapy in a randomized clinical trial vs. an observational study: CALGB #49907 and #369901
Mandelblatt JS, Makgoeng SB, Luta G, Hurria A, Kimmick G, Isaacs C, Tallarico M, Barry WT, Pitcher B, Winer EP, Hudis C, Cohen HJ, Muss HB. A planned, prospective comparison of short-term quality of life outcomes among older patients with breast cancer treated with standard chemotherapy in a randomized clinical trial vs. an observational study: CALGB #49907 and #369901. Journal Of Geriatric Oncology 2013, 4: 353-361. PMID: 24472479, PMCID: PMC3910230, DOI: 10.1016/j.jgo.2013.05.004.Peer-Reviewed Original ResearchConceptsRandomized clinical trialsOlder womenStandard chemotherapyClinical trialsProspective comparisonObservational studyBreast cancerNon-metastatic breast cancerOlder cancer populationPre-treatment QoLTherapy side effectsBreast cancer chemotherapyShort-term qualityAdjusted mean increaseQuality of lifeTumor factorsOlder patientsAnthracycline regimensQOL scoresGlobal QoLCancer populationSide effectsGroup physiciansChemotherapyLinear mixed effects modelsTBCRC 018: Phase II study of iniparib plus chemotherapy to treat triple-negative breast cancer (TNBC) central nervous system (CNS) metastases (mets).
Anders C, Deal A, Abramson V, Liu M, Storniolo A, Carpenter J, Puhalla S, Nanda R, Melhem-Bertrandt A, Lin N, Marcom P, Van Poznak C, Stearns V, Melisko M, Smith J, Karginova O, Winer E, Perou C, Wolff A, Carey L. TBCRC 018: Phase II study of iniparib plus chemotherapy to treat triple-negative breast cancer (TNBC) central nervous system (CNS) metastases (mets). Journal Of Clinical Oncology 2013, 31: 515-515. DOI: 10.1200/jco.2013.31.15_suppl.515.Peer-Reviewed Original ResearchQuality of lifeBlood-brain barrierResponse rateCommon grade 3/4 adverse eventsCentral nervous system metastasesGrade 3/4 adverse eventsClinical benefit rateNervous system metastasesPhase II studyTumor response rateKaplan-Meier methodWhole brain RTHalf of womenBetter response rateSmall molecule anti-cancer agentTopoisomerase I inhibitorAdvanced TNBCCorrelative endpointsEligible ptsGermline BRCA1/2Measurable lesionsMedian TTPRadiation-naïveAnti-cancer agentsPrimary endpointQuality of life and psychosocial distress in young women with advanced breast cancer.
Seah D, Gelber S, Ruddy K, Tamimi R, Schapira L, Come S, Meyer M, Larsen B, Winer E, Partridge A. Quality of life and psychosocial distress in young women with advanced breast cancer. Journal Of Clinical Oncology 2013, 31: e20508-e20508. DOI: 10.1200/jco.2013.31.15_suppl.e20508.Peer-Reviewed Original ResearchAdvanced breast cancerQuality of lifePsychosocial distressBreast cancerYoung womenBodily painSF-36 subscale scoresBaseline surveyLongitudinal multi-centre studyMedical chart dataMental health scoresMulti-center studySocial functioningABC diagnosisABC patientsClinical factorsMedian ageMedian timeClinical variablesRole limitationsGeneral healthDepressed womenHealth scoresGeneral populationLogistic regressionInternational guidelines for management of metastatic breast cancer (MBC) from the European School of Oncology (ESO)–MBC Task Force: Surveillance, staging, and evaluation of patients with early-stage and metastatic breast cancer
Lin NU, Thomssen C, Cardoso F, Cameron D, Cufer T, Fallowfield L, Francis PA, Kyriakides S, Pagani O, Senkus E, Costa A, Winer EP, Force E. International guidelines for management of metastatic breast cancer (MBC) from the European School of Oncology (ESO)–MBC Task Force: Surveillance, staging, and evaluation of patients with early-stage and metastatic breast cancer. The Breast 2013, 22: 203-210. PMID: 23601761, DOI: 10.1016/j.breast.2013.03.006.Peer-Reviewed Original ResearchConceptsMetastatic breast cancerEarly-stage breast cancerBreast cancerTumor markersRisk/benefit ratioEuropean Breast Cancer ConferenceEarly-stage patientsEvaluation of patientsInitiation of treatmentProgression of diseaseSpecific BC subtypesTask ForceQuality of lifeType of treatmentEndocrine therapyMetastatic diseaseMetastatic involvementSystemic therapyBC subtypesPhysical examinationClinical trialsCancer ConferencePatientsClinical practiceInternational guidelinesQuality of life and symptoms in male breast cancer survivors
Ruddy KJ, Giobbie-Hurder A, Giordano SH, Goldfarb S, Kereakoglow S, Winer EP, Partridge AH. Quality of life and symptoms in male breast cancer survivors. The Breast 2013, 22: 197-199. PMID: 23313328, DOI: 10.1016/j.breast.2012.12.014.Peer-Reviewed Original ResearchConceptsMale breast cancer survivorsBreast cancer survivorsQuality of lifeCancer survivorsProstate Cancer Index CompositeCancer Therapy-BreastFACT-B scoresHormonal scoresHormonal symptomsSymptom burdenBreast cancerStage 0Depression ScaleFunctional assessmentHospitalized AnxietyMale survivorsSymptomsSurvivorsSexual scaleOverall qualityScoresPatientsCancer
2012
Randomized trial of a physical activity intervention in patients with metastatic breast cancer.
Ligibel J, Giobbie-Hurder A, Shockro L, Campbell N, Partridge A, Tolaney S, Lin N, Winer E. Randomized trial of a physical activity intervention in patients with metastatic breast cancer. Journal Of Clinical Oncology 2012, 30: 9084-9084. DOI: 10.1200/jco.2012.30.15_suppl.9084.Peer-Reviewed Original ResearchMetastatic breast cancerDiagnosis of MBCPhysical activity interventionsPA interventionsBreast cancerActivity interventionsModerate-intensity PA interventionUsual care control groupEarly-stage breast cancerPhysical Activity Recall interviewFunctional measuresActive brain metastasesEORTC QLQ CCare control groupBruce treadmill testQuality of lifeECOG 0Brain metastasesHormonal therapyQLQ CBiologic therapyMedian ageIntervention armMedian timeTreadmill timeQuality of Life in Long-Term Survivors of Metastatic Breast Cancer
Meisel JL, Domchek SM, Vonderheide RH, Giobbie-Hurder A, Lin NU, Winer EP, Partridge AH. Quality of Life in Long-Term Survivors of Metastatic Breast Cancer. Clinical Breast Cancer 2012, 12: 119-126. PMID: 22444718, DOI: 10.1016/j.clbc.2012.01.010.Peer-Reviewed Original ResearchConceptsMetastatic breast cancerBreast cancerHormone receptor-positive diseaseNode-positive diseaseCancer Therapy-BreastLong-term survivorsSubset of womenHADS anxiety scoreHADS depression scorePopulation of womenFunctional Social Support QuestionnaireFisher's exact testQuality of lifeWilcoxon rank sum testCross-sectional surveyIES-R scaleRank sum testNorth Carolina Functional Social Support QuestionnaireAdjuvant therapyEligible womenPositive diseaseSpearman correlation coefficientDisease characteristicsHospital AnxietyMedical history
2011
OT3-02-04: TBCRC 012: ABCDE, a Phase II Randomized Study of Adjuvant Bevacizumab, Metronomic Chemotherapy (CM), Diet and Exercise after Preoperative Chemotherapy for Breast Cancer.
Mayer E, Ligibel J, Burstein H, Peppercorn J, Miller K, Carey L, Dickler M, Mayer I, Forero A, Eng-Wong J, Pletcher P, Ryabin N, Gelman R, Wolff A, Winer E. OT3-02-04: TBCRC 012: ABCDE, a Phase II Randomized Study of Adjuvant Bevacizumab, Metronomic Chemotherapy (CM), Diet and Exercise after Preoperative Chemotherapy for Breast Cancer. Cancer Research 2011, 71: ot3-02-04-ot3-02-04. DOI: 10.1158/0008-5472.sabcs11-ot3-02-04.Peer-Reviewed Original ResearchPreoperative chemotherapyBreast cancerLifestyle interventionPhase II Randomized StudyAcceptable organ functionResidual invasive diseaseAdjuvant combination chemotherapyTaxane-based chemotherapyRecurrence-free survivalResidual breast cancerRisk of recurrenceFuture clinical trialsStructured exercise programImpact of exerciseAnti-angiogenic agentsUnmet medical needContribution of exerciseQuality of lifeYear BAdjuvant bevacizumabDFCI 05Eligible ptsLast surgeryNeoadjuvant chemotherapyPrimary endpointQuality of Life of Older Patients With Early-Stage Breast Cancer Receiving Adjuvant Chemotherapy: A Companion Study to Cancer and Leukemia Group B 49907
Kornblith AB, Lan L, Archer L, Partridge A, Kimmick G, Hudis C, Winer E, Casey R, Bennett S, Cohen HJ, Muss HB. Quality of Life of Older Patients With Early-Stage Breast Cancer Receiving Adjuvant Chemotherapy: A Companion Study to Cancer and Leukemia Group B 49907. Journal Of Clinical Oncology 2011, 29: 1022-1028. PMID: 21300923, PMCID: PMC3068052, DOI: 10.1200/jco.2010.29.9859.Peer-Reviewed Original ResearchMeSH KeywordsAge FactorsAgedAntimetabolites, AntineoplasticAntineoplastic Combined Chemotherapy ProtocolsBreast NeoplasmsCapecitabineChemotherapy, AdjuvantCyclophosphamideDeoxycytidineDisease-Free SurvivalDoxorubicinFemaleFluorouracilHumansMethotrexateNeoplasm StagingQuality of LifeRisk AssessmentRisk FactorsSurveys and QuestionnairesSurvival AnalysisTime FactorsTreatment OutcomeUnited StatesConceptsEarly-stage breast cancerSystemic adverse effectsStandard chemotherapyBreast cancerCapecitabine treatmentOlder patientsOverall survivalStandard treatmentBetter QOLAdverse effectsHand-foot syndromePhase III trialsLife Questionnaire C30Completion of treatmentQuality of lifeAdjuvant chemotherapyLife substudyIII trialsCancer QualityImproved survivalLess nauseaGood appetiteHospital AnxietyDepression ScaleMonths postbaseline